LFWD
Lifeward Ltd.
$6.98
-0.36%
$19.6M
No data for this timeframe.
Vol
Market Cap$19.6M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
SEC Reports10
Press Releases4
Exchange Nasdaq·Sector Orthopedic, Prosthetic & Surgical Appliances & Supplies·Inc. L3·CIK 0001607962·Prev Close $7.01
Recent Activity
May 19, 2026
SEC
Lifeward Ltd. announced the appointment of Dr. Keith D. Rose, an internal promotion from VP Medical Affairs to Chief Med
8-K — Impact 2/10
May 19, 2026
other
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
<p align="center"><em>Veteran physician</em><em>, </em><em>medical affairs</em><em> and clinical res
May 15, 2026
SEC
Lifeward reported Q1 2026 revenue of $3.9M (down 22% YoY) and a GAAP net loss of $10.8M ($6.70/share), massively missing
PRESS-RELEASE — Impact 7/10
May 15, 2026
SEC
Lifeward reported Q1 2026 revenue of $3.9M, down 22% YoY from $5.0M, and a GAAP net loss of $10.8M ($6.70/share) vs $4.8
8-K — Impact 6/10
May 1, 2026
Insider
Rose Keith Dale sold 15,000 shares
Chief Medical Officer @ $0.00 ($0.00)
Mar 25, 2026
Press
Lifeward Ltd. has closed a strategic partnership with Oramed Pharmaceuticals, acquiring Oramed's clinical-stage Protein
Impact 8/10
Mar 25, 2026
Insider
Kidron Miriam sold 7,657 shares
Director @ $0.00 ($0.00)
Mar 25, 2026
Insider
KIDRON NADAV sold 7,657 shares
Director @ $0.00 ($0.00)
Price Targets
$20.00
+186.4% upside
Strong Buy
Current $6.98
Low $10.00
Median $20.00
High $30.00
2 analysts
$10.00
$30.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 19, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.28 | $-1.28 — $-1.28 | 66% YoY | 1 |
| Next Q | $-0.94 | $-0.94 — $-0.94 | 59% YoY | 1 |
| Current FY | $-4.58 ▼ -20.5% | $-4.58 — $-4.58 | 65% YoY | 1 |
| Next FY | $-1.81 ▼ -55.4% | $-1.90 — $-1.72 | 65% YoY | 2 |
Latest Reports
NEUTRAL
8-K
2/10
Lifeward Ltd. announced the appointment of Dr. Keith D. Rose, an internal promotion from VP Medical Affairs to Chief Med
May 19, 2026
BEARISH
PRESS-RELEASE
7/10
Lifeward reported Q1 2026 revenue of $3.9M (down 22% YoY) and a GAAP net loss of $10.8M ($6.70/share), massively missing
May 15, 2026
BULLISH
Press
8/10
Lifeward Ltd. has closed a strategic partnership with Oramed Pharmaceuticals, acquiring Oramed's clinical-stage Protein
Mar 25, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | Rose Keith | A | $0.00 |
| Mar 25, 2026 | Kidron Miriam | A | $0.00 |
| Mar 25, 2026 | KIDRON NADAV | A | $0.00 |
| Mar 25, 2026 | Reznick Yehuda | A | $0.00 |
| Mar 25, 2026 | Grant William | A | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
8 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | Rose Keith Dale | Chief Medical Officer | A | 15,000 | $0.00 | $0.00 |
| Mar 25, 2026 | Kidron Miriam | Director | A | 7,657 | $0.00 | $0.00 |
| Mar 25, 2026 | KIDRON NADAV | Director | A | 7,657 | $0.00 | $0.00 |
| Mar 25, 2026 | Reznick Yehuda | Director | A | 7,657 | $0.00 | $0.00 |
| Mar 25, 2026 | Grant William Mark | President & CEO | A | 172,698 | $0.00 | $0.00 |
| Mar 25, 2026 | Adar Almog | Chief Financial Officer | A | 39,934 | $0.00 | $0.00 |
| Mar 25, 2026 | Rozenbaum Moshe H | Director | A | 11,485 | $0.00 | $0.00 |
| Mar 25, 2026 | Sigsbee William Mark | Director | A | 11,485 | $0.00 | $0.00 |
10 SEC filing reports analyzed. Sentiment: 0 bullish, 4 bearish, 0 mixed, 6 neutral. Avg impact: 4.5/10.
NEUTRAL
8-K
2/10
Lifeward Ltd. announced the appointment of Dr. Keith D. Rose, an internal promotion from VP Medical
May 19, 2026
BEARISH
PRESS-RELEASE
7/10
Lifeward reported Q1 2026 revenue of $3.9M (down 22% YoY) and a GAAP net loss of $10.8M ($6.70/share
May 15, 2026
BEARISH
8-K
6/10
Lifeward reported Q1 2026 revenue of $3.9M, down 22% YoY from $5.0M, and a GAAP net loss of $10.8M (
May 15, 2026
BEARISH
EFFECT
8/10
The SEC declared effective Lifeward's Form S-3 registration statement (File 333-295352) filed on Apr
May 13, 2026
NEUTRAL
PRESS-RELEASE
2/10
Lifeward announced it will report Q1 2026 financial results on May 15, 2026, before market open. The
May 11, 2026
BEARISH
S-3
8/10
Lifeward Ltd. filed an S-3 registration statement on April 27, 2026, registering 7,256,474 ordinary
Apr 27, 2026
NEUTRAL
3
2/10
Nadav Kidron, a reporting person for Lifeward Ltd., filed a Form 3 to report initial beneficial owne
Mar 27, 2026
NEUTRAL
3
2/10
Miriam Kidron, a reporting person for Lifeward Ltd., filed a Form 3 to report her initial beneficial
Mar 27, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing for Lifewa
Mar 18, 2026
NEUTRAL
8-K
4/10
Lifeward Ltd. (LFWD) entered into an agreement to acquire intellectual property and technology asset
Feb 25, 2026
BULLISH
8/10
Lifeward Ltd. has closed a strategic partnership with Oramed Pharmaceuticals, acquiring Oramed's cli
Mar 25, 2026
MIXED
6/10
Lifeward reported declining revenue and earnings for Q4 and full-year 2025, with Q4 revenue down 33%
Mar 18, 2026
MIXED
6/10
Lifeward announced shareholder approval of a strategic partnership with Oramed Pharmaceuticals, inte
Mar 13, 2026
NEUTRAL
3/10
Lifeward Ltd. announced it will release its Q4 and full-year 2025 financial results on March 18, 202
Mar 10, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$20.00 mean target
+186.4% upside
Strong Buy (1.50)
$10.00 Low
$30.00 High
| Metric | Value |
|---|---|
| Current Price | $6.98 |
| Target Low | $10.00 |
| Target Mean | $20.00 |
| Target Median | $20.00 |
| Target High | $30.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.28 | $-1.28 | $-1.28 | 65.6% | — | — | $0.0B | 14.1% | 1 |
| Next Q 2026-09-30 |
$-0.94 | $-0.94 | $-0.94 | 58.8% | — | — | $0.0B | 37.9% | 1 |
| Current FY 2026-12-31 |
$-4.58 | $-4.58 | $-4.58 | 65.4% | -20.5% | 0↑ 1↓ | $0.0B | 28.4% | 1 |
| Next FY 2027-12-31 |
$-1.81 | $-1.90 | $-1.72 | 65.1% | -55.4% | 0↑ 2↓ | $0.1B | 82.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.280 | |
| 7d ago | $0.000 | -1.280 |
| 30d ago | $0.000 | -1.280 |
| 60d ago | $0.000 | -1.280 |
| 90d ago | $0.000 | -1.280 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 19, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 19, 2026
other
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
<p align="center"><em>Veteran physician</em><em>, </em><em>medical affairs</em><em> and clinical research</em><em> leader</em> <em>brings 30 years of
May 15, 2026
earnings
Lifeward Reports First Quarter 2026 Financial Results
<p align="center"><em>Oramed </em><em>strategic </em><em>transaction</em> <em>successfully </em><em>closed</em><em> and $10 million </em><em>financing
May 15, 2026
earnings_calendar
LFWD Q1 2026 Earnings Scheduled — 2026-05-15
May 13, 2026
earnings_calendar
LFWD Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings
Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026
<p align="justify">HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=xi_
May 7, 2026
earnings_calendar
LFWD Q1 2026 Earnings Scheduled — 2026-05-07
Mar 25, 2026
contract
Lifeward Successfully Closes on Strategic Partnership with Oramed
<p align="justify" style="text-align: justify;"> </p>
Mar 18, 2026
earnings
Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results
<p align="center"> </p>
Mar 13, 2026
contract
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
<p align="center"><em>Position</em><em>s</em><em> Lifeward as a diversified biomedical innovation </em><em>company</em><em> with </em><em>clear </em><
Mar 11, 2026
other
Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement
<p align="justify">HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Comp
Mar 10, 2026
earnings
Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
<p align="justify">MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the